Eucrates Biomedical Acquisition Corp. operates as a blank Check company focusing on acquiring, engaging in a share exchange, share reconstruction and amalgamations. The company was founded by Stelios Papadopoulos, Parag Saxena, Evangelos Vergetis and Daphne Karydas on August 21, 2020 and is headquartered in New York, NY.
Sector:
Finance
Industry:
Financial Conglomerates
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Eucrates Biomedical Acquisition Corp?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Eucrates Biomedical Acquisition Corp market cap is $42.23M.
What is the 52-week high for Eucrates Biomedical Acquisition Corp?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Eucrates Biomedical Acquisition Corp 52 week high is $10.25 as of October 10, 2025.
What is the 52-week low for Eucrates Biomedical Acquisition Corp?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Eucrates Biomedical Acquisition Corp 52 week low is $9.87 as of October 10, 2025.
What is Eucrates Biomedical Acquisition Corp stock price today?
Eucrates Biomedical Acquisition Corp stock price today is $10.04.
What was Eucrates Biomedical Acquisition Corp stock price yesterday?
Eucrates Biomedical Acquisition Corp stock price yesterday was $10.04.
What is the PE ratio of Eucrates Biomedical Acquisition Corp?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Eucrates Biomedical Acquisition Corp’s P/E ratio is 53.46.
What is the Price-to-Book ratio of Eucrates Biomedical Acquisition Corp?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Eucrates Biomedical Acquisition Corp P/B ratio is 1.3302.
What is the 50-day moving average of Eucrates Biomedical Acquisition Corp?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Eucrates Biomedical Acquisition Corp 50-day moving average is $10.11.
